Annual Congress Amsterdam 2011

Saturday, 24.09.2011
Sunday, 25.09.2011
Monday, 26.09.2011
Tuesday, 27.09.2011
Wednesday, 28.09.2011

Citations should be made in the following way: Authors. Title. Eur Respir J 2011; 38: Suppl. 55, abstract number.

Material from 2011

4205 Abstracts
632 Slide presentations
250 Webcasts
66 Handouts
1703 e-posters
250 Multimedia files

Material from 2011 Show

Drug delivery and pharmacokinetics II

Thematic Poster Session
Chairs: O. Usmani (London, United Kingdom), M. Molimard (Bordeaux, France), H. Chrystyn (Huddersfield, United Kingdom), J. C. Virchow (Rostock, Germany)

Download all media

Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects A. Cahn, R. Lovick, A. Newlands, A. Deans, I. Pouliquen, A. Preece, D. Kelleher, R. Mehta, R. Tal-Singer (Stevenage, Uxbridge, United Kingdom; Research Triangle Park, King of Prussia, United States Of America)
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults R. Mehta, K. Hardes, A. Cahn, A. Newlands, A. Donald, A. Preece, D. Kelleher, G. Crater (Research Triangle Park, United States Of America; Uxbridge, Stevenage, United Kingdom)
The pharmacokinetics (PK) and pharmacodynamics (PD) of repeat inhaled administration of fluticasone furoate (FF) in healthy Caucasian, Chinese, Japanese and Korean subjects A. Allen, J. Bal, A. Cheesbrough, M. Hamilton, R. Kempsford (Stevenage, Stockley Park, Uxbridge, Ware, United Kingdom)
The pharmacokinetics (PK) of fluticasone furoate (FF) in healthy Caucasian, Chinese, Japanese and Korean subjects A. Allen, J. Bal, A. Cheesbrough, M. Hamilton, R. Kempsford (Stevenage, Stockley Park, Uxbridge, Ware, United Kingdom)
Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD C. Orevillo, E. St. Rose, S. Strom, T. Fischer, M. Golden, M. Thomas, C. Reisner (Morristown, Raleigh, United States Of America; Toowong, Australia)
The absolute bioavailability of fluticasone furoate (FF) and vilanterol (VI) trifenatate following inhaled administration in combination in healthy subjects A. Allen, J. Bianco, J. Bal, L. Tombs, R. Kempsford (Stevenage, Uxbridge, Slough, United Kingdom; Randwick, Australia)
No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin R. Frey, W. Mück, S. Unger, M. Reber, J. Krätzschmar, C. Becker, G. Wensing (Wuppertal, Germany)
How can we improve patient use of inhaler devices in COPD? M. Molimard, K. Giorgi-Vigo (Bordeaux, France; Basel, Switzerland)
Patient assessments of ease of use of Genuair® versus Aerolizer® and HandiHaler® R. Fuhr, H. Magnussen, D. Singh, G. de Miquel, C. Caracta, E. Garcia Gil (Berlin, Grosshansdorf, Germany; Manchester, United Kingdom; Barcelona, Spain; , United States Of America)
Comparison of the bronchoprotective effects of two salbutamol suplphate HFA pMDI using methacholine challenge testing J. Rebello, M. Mangale, S. Chachad, G. Malhotra, S. Purandare, S. Salvi, B. Brashier, A. Mesquita, L. Fernandes, G. D‘Souza (Mumbai, Pune, Panaji, Banglore, India)
Preference of the inhaler device and assessment of the technique among the asthmatic and COPD patients W. Tarsin, I. Alshamli, M. Soussi (Tripoli, Triploi, Libyan Arab Jamahiriya)
Pharmacokinetic evaluation of two HFA pMDI formulations of salmeterol xinafoate administered through a spacer in healthy subjects S. Chandran, N. Morde, J. Rebello, S. Chachad, S. Purandare, G. Malhotra, R. Jadhav, K. Iyer, R. Naidu (Mumbai, India)
The aerodynamic particle size of mometasone furoate 100 μg and 200 μg dry powder formulations R. Berger, S. Li, H. Staudinger (Kenilworth, United States Of America)
Safety and tolerability of single doses of AZD5069 in healthy volunteers H. Wray, A. Sparrow (Loughborough, United Kingdom)
No significant clinical drug-drug interaction potential with indacaterol S. Perry, P. Goldsmith, S. Vaidyanathan, P. Bhad, H. Einolf, R. Woessner, G. Kaiser, S. Jennings, B. Patterson (Horsham, United Kingdom; Hyderabad, India; East Hanover, United States Of America; Basel, Switzerland)
Fluticasone propionate/formoterol fumarate combination therapy is equally effective and well-tolerated when administered with or without a spacer device to patients with asthma D. Price, A. Papi, K. Kaiser, B. Grothe, M. Lomax (Aberdeen, Cambridge, United Kingdom; Ferrara, Italy; Muttenz, Switzerland)
Effects of steady-state female hormones on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide N. Nassr, A. Hünnemeyer, R. Herzog, J. Scholpp, G. Lahu (Konstanz, Germany)
Lack of effect of mild and moderate hepatic impairment or UGT1A1 genotype on the pharmacokinetics of inhaled indacaterol P. Goldsmith, S. Perry, H. He, R. Woessner, G. Kaiser (Horsham, United Kingdom; East Hanover, United States Of America; Basel, Switzerland)
In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs) D. von Hollen, L. Slator, K. Nikander, R. Hatley (Parsippany, United States Of America; Chichester, United Kingdom)
Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone D. S. Pearlman, C. LaForce, K. Kaiser (Denver, Raleigh, United States Of America; Muttenz, Switzerland)